Alzheimer’s blood tests are becoming more widely available and at-home, transforming care and offering early detection. Dr. Fillit shares with @aarp.org how these tests are not a stand-alone diagnosis; clinical evaluation is still essential. www.aarp.org/health/condi...

At #CTAD2025, Novo Nordisk shared new phase 3 results from Evoke/Evoke+ trials, offering important insights that underscore a critical shift toward the next era of drug development, which will target the underlying biology of this complex disease. bit.ly/4iMH1WH

Topline results from the Evoke & Evoke+ Phase 3 trials show new insights despite missed endpoints. ADDF’s early support helps advance research, and the data will guide future combination therapy strategies for #Alzheimer’s. bit.ly/4rgojdS

Mark Roithmayr, ADDF CEO, shares his journey in #philanthropy, reflecting on the lessons, people, & moments that shaped his leadership and impact on Team Powdered Donut. Tune in for a conversation full of heart and purpose-driven leadership, driving real-world change. bit.ly/3M9s5FG

The ADDF is proud to partner with JPAD on a landmark issue on combination therapies. Just as they transformed cancer care, combination therapies are poised to do the same for #Alzheimer’s, providing a roadmap for advancing critical research. bit.ly/3XqcdRA

A new CBS Sunday segment spotlights how partnerships are driving optimism in Alzheimer’s research. @billgates.bsky.social highlights how breakthroughs in blood tests, biomarkers & AI, spearheaded by the Diagnostics Accelerator, are reshaping the field. www.cbsnews.com/news/promisi...

The Annual Fall Symposium & Luncheon celebrated 27 years of vision from Leonard & Ronald Lauder, inspiring science & honorees! Phebe Farrow Port received the Charles Evans Award and Martha & Peter Webster received the Visionary Partner Award. bit.ly/47letQ0

The ADDF celebrates the opening of the Center for Aging Well at Yale Nursing, led by Dr. Miia Kivipelto. Her pioneering work in brain health and aging continues to shape the future of precision prevention and #Alzheimer’s care. bit.ly/4hFhUVe

In a special Power of Ideas series, Howard Fillit highlighted the pivotal inflection point #Alzheimer’s science has reached in recent years. The ADDF is driving #breakthroughs through bold partnerships and cross-sector #collaboration. @milkeninstitute.org milkeninstitute.org/content-hub/...

Can GLP-1s also combat Alzheimer’s? Novo Nordisk’s EVOKE trial results will be presented at CTAD, building on ADDF-funded research by Dr. Paul Edison on liraglutide. Repurposed drugs & precision medicine could redefine how we treat #Alzheimer’s. on.ft.com/3J1HpTU

The World Dementia Council is hosting a virtual event on “Lessons from innovators: biomarkers.” Supported by @theaddf.bsky.social, this dialogue will explore rapid advances & key challenges in developing new dementia diagnostics. More here: bit.ly/4kUT4Re

Alzheimer’s care is evolving. The FDA clearance of Roche and @elilillyandcompany.bsky.social Elecsys pTau181 blood test marks a major step toward accessible, scalable diagnostics that bring detection into everyday clinical care. @cnn.com

We’re proud to celebrate Eisai and Biogen for Leqembi Iqlik being named one of TIME's Best Inventions of 2025. This marks incredible innovation in Alzheimer’s care, paving the way for faster & simpler delivery that can be self-administered at home like GLP-1s. bit.ly/4q9P976

Congratulations to our friend and partner Anne White, who has been named one of Endpoints News’ Women in Biopharma 2025. Anne’s impact and leadership at @elilillyandcompany.bsky.social from advancing oncology to Alzheimer’s breakthroughs continues to transform the field. bit.ly/3INh5wG

The conversation around Alzheimer’s care is shifting. Dr. Jason Karlawish explores how advances in disease-modifying therapies and novel diagnostics are transforming society at large—a future defined by combination therapy and precision medicine. bit.ly/3KD9IIx

Today, our partners C2N Diagnostics submitted the #PrecivityAD2 blood test to the #FDA for approval, enabling earlier diagnosis and intervention for Alzheimer's treatment, a core tenet of the ADDF's DxA. The next frontier is precision medicine. bit.ly/46Lw4yV

The ADDF’s DxA announced two milestones: the release of #SpeechDx’s first data tranche & a new partnership with Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s. bit.ly/4ohctOz

Missed our latest webinar? Tune in to an extraordinary conversation with the ADDF’s scientific leaders, Aaron Burstein, PharmD, and Melissa Lee, PhD, as they discuss the cutting-edge #Alzheimer’s research in 2025, fueled by the ADDF’s bold vision. www.youtube.com/watch?v=I_XO...

The European Commission has authorized #Kisunla, marking a new era in #Alzheimer's treatment and accelerating global innovation. This milestone expands access for patients and families, enabling early detection and treatments that help slow decline. @elilillyandcompany.bsky.social bit.ly/46mYY9M

Alzheimer’s is undergoing a diagnostic revolution. A new series from The Lancet explores how advances in biomarkers are transforming diagnosis, enabling more equitable and affordable access to treatment, which speaks to the DxA’s mission. bit.ly/4pFkVID

A new era of Alzheimer's treatment is here. Dr. Fillit shares with @sciam.bsky.social that the future lies in precision combination therapies, like in cancer. The path forward will combine anti-amyloid and tau therapies with novel treatments that target the biology of aging, such as inflammation.

With advances in #AI-powered tools, Melissa Lee, PhD, highlights the ADDF’s Diagnostics Accelerator vision: a future where blood tests, speech samples, and digital tools enable early detection and personalized care for #Alzheimer’s. www.linkedin.com/pulse/what-w...

On the latest episode of Managed Care Cast, Dr. Fillit and Dr. Anthony Sireci, @elilillyandcompany.bsky.social, discuss a transformative milestone in Alzheimer’s care: the first-ever FDA clearance for a blood test, the Lumipulse plasma assay. bit.ly/47GLnv8

Alzheimer’s Disease: Diagnosis & Treatment: Blood tests that show biomarkers for Alzheimer’s disease can delay onset of symptoms. . Learn more here: bbrfoundation.org/healthy-mind... . @theaddf.bsky.social @pbs.org #mentalhealth

#GLP-1s have the potential to redefine #Alzheimer's treatment. @a_hfillit shared with #Bloomberg that #semaglutide could become “one of the first anti-aging drugs,” bringing Alzheimer’s care closer to combination therapies & precision medicine, like in cancer. bloom.bg/4nipzdO

Today marks a great step forward with the first-ever #FDA approval of the subcutaneous formulation of #Leqembi (lecanemab), a major advancement ushering in the next gen of #Alzheimer’s care with combination therapy and precision medicine. bit.ly/47Pga8Y

Healthcare startups are turning to venture philanthropy to advance bold ideas amid a challenging funding environment. Karen Harris shares how the ADDF bridges the gap with investments and a willingness to support high-risk, early-stage science. wewillcure.com/insights/inv...

New 4-year CLARITY AD data show #lecanemab slows decline & improves function in #Alzheimer’s. Dr. Howard Fillit tells Medscape this is a major advancement in reducing progression risk by 34%. This data brings us closer to #precision #medicine in Alzheimer’s care. wb.md/3H2BUn0